Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 17, 2006

MDS Pharma Services Opens U.S. Central Lab

  • MDS Pharma Services established its first central lab in the U.S. The new 15,000-sq-ft facility, located in North Brunswick, NJ, expands MDS Pharma Services’ capabilities in late-stage pharmaceutical testing. It also provides central lab support services for clinical trials. In addition to standard safety testing, the company reports that this facility provides esoteric testing, including molecular biology, molecular genetics, flow cytometry, and immunoassays.

    “We established this lab to meet the growing demand from clients for a facility in the United States that offers both standard and complex testing to support the development of new treatments,” comments David Spaight, president. “This location is easily accessible to many pharmaceutical companies headquartered in the Northeastern United States. It can accommodate clients who conduct clinical trials in and outside thecountry.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »